Comparative efficacy of trastuzumab deruxtecan versus guideline-recommended treatments for 2L+ unresectable locally advanced or metastatic HER2-mutant non-small cell lung cancer: a systematic review and indirect treatment comparison

IntroductionThe clinical benefit of trastuzumab deruxtecan (T-DXd 5.4mg/kg), the first approved HER2-directed therapy for patients with previously treated HER2-mutant (HER2m) non-small cell lung cancer (NSCLC), was demonstrated in the phase II DESTINY-Lung02 trial. This study evaluated the efficacy...

Πλήρης περιγραφή

Λεπτομέρειες βιβλιογραφικής εγγραφής

Κύριοι συγγραφείς:	Federico Cappuzzo, Lirong Zhang, Kyle Dunton, Natalie Dennis, Pauline Le Nouveau, Agathe Nevière, Aline Gauthier
Μορφή:	Artigo
Γλώσσα:	Inglês
Έκδοση:	Frontiers Media S.A. 2026-02-01
Σειρά:	Frontiers in Oncology
Θέματα:	HER2 mutation matching-adjusted indirect comparison network meta-analysis NSCLC trastuzumab deruxtecan
Διαθέσιμο Online:	https://www.frontiersin.org/articles/10.3389/fonc.2025.1708245/full
Ετικέτες:	Προσθήκη ετικέτας Δεν υπάρχουν, Καταχωρήστε ετικέτα πρώτοι!